NAION and ischaemic neuropathy comparison

Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION)

Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) is the most frequent cause of acute optic neuropathy in individuals over the age of 50, with an estimated annual incidence of 2 to 10 per 100,000. It is a multifactorial, localized microvascular hypoperfusion disorder affecting the short posterior ciliary arteries supplying the prelaminar and laminar optic nerve head, in the absence of systemic vasculitis.

Pathogenesis & Structural Predisposition: The "Disc at Risk"

NAION occurs as a consequence of transient microcirculatory hypoperfusion within a structurally vulnerable optic nerve head:

• The Anatomical "Disc at Risk" / Crowded Disc: The primary predisposing anatomical factor is a small, crowded optic disc characterized by a small scleral canal and a small or absent physiological cup (cup-to-disc ratio $\le 0.1-0.2$). In these tightly packed discs, approximately 1.2 million retinal ganglion cell axons squeeze through a rigid, unyielding scleral aperture. When minor ischaemia occurs, the resulting axonal oedema creates a secondary compartment syndrome within the tight scleral ring, compressing adjacent capillaries, worsening ischaemia, and triggering widespread axonal infarction.

Systemic Vascular Risk Factors

• Nocturnal Arterial Hypotension: The physiological "nocturnal dip" in systemic blood pressure reduces ocular perfusion pressure ($\text{OPP} = \text{Mean Arterial Pressure} - \text{Intraocular Pressure}$). This is frequently exacerbated by taking systemic antihypertensive medications at bedtime.
• Systemic Comorbidities: Systemic hypertension, diabetes mellitus, hypercholesterolaemia, cardiovascular disease, and smoking.
• Obstructive sleep apnoea: An important association and potentially modifiable systemic risk; screen according to symptoms and clinical context rather than assuming a fixed prevalence.
• Phosphodiesterase Type 5 (PDE-5) Inhibitors: Medications such as sildenafil, tadalafil, and vardenafil induce mild systemic vasodilation and nocturnal hypotension; temporal associations with NAION onset have been well documented.

Clinical Presentation & Cardinal Signs

• "Morning Discovery": Patients classically discover sudden, painless, unilateral visual loss upon awakening in the morning (reflecting the nocturnal hypotensive insult).
• Visual Acuity: Variable, ranging from 20/20 to count fingers (median acuity ~20/60). Over 50% have visual acuity of 20/60 or better.
• Visual Field Defect: The hallmark perimetric finding is an altitudinal visual field defect, most commonly an inferior altitudinal scotoma that sharply respects the horizontal midline. This reflects the watershed partition between superior and inferior SPCA supplies.
• Fundus Appearance: Optic disc oedema is typically hyperaemic or segmental (swollen superiorly with an inferior field defect, or vice versa), often accompanied by flame-shaped peripapillary splinter haemorrhages. Over 6 to 8 weeks, the swelling resolves, giving way to sectoral or generalized optic atrophy.
• Fellow Eye Examination: Crucially, funduscopy of the fellow unaffected eye demonstrates the characteristic "disc at risk" (absent cup, crowded disc).

Natural History & Management

• Visual Acuity Course: Unlike AAION, spontaneous visual acuity improvement of $\ge 3$ Snellen lines occurs in approximately 40% of NAION patients over the first 3 to 6 months. However, visual field defects rarely resolve.
• Recurrence in the Same Eye: True recurrence in the previously affected eye is extremely rare ($<5\%$), because the resultant optic atrophy ("pseudo-cup") decompresses the scleral canal, eliminating the crowded compartment effect.
• Fellow-Eye Involvement Risk: The 5-year risk of NAION developing in the fellow eye is approximately 15% to 20%.
• Treatment Evidence: The landmark Ischemic Optic Neuropathy Decompression Trial (IONDT) demonstrated that optic nerve sheath decompression surgery is completely ineffective and potentially harmful in NAION (surgical patients fared worse than observed controls). No medical therapy (including corticosteroids, aspirin, or neuroprotective agents) has been conclusively proven to reverse visual loss in randomised controlled trials. Clinical management focuses on modifiable risk factors: screening and treating sleep apnoea, addressing smoking, diabetes and lipids, and reviewing blood-pressure patterns and potentially associated medicines with the treating physician. Do not impose an automatic antihypertensive timing change or lifelong drug prohibition.

Diagnostic Comparison: AAION (GCA) vs. NAION

The following table contrasts the essential features required to differentiate AAION from NAION:

NAION Risk Review

A crowded fellow disc and sectoral swelling support NAION in the appropriate setting after excluding GCA and other causes. Address vascular risk, smoking and sleep apnoea with the physician. Nocturnal hypotension and some medicines are possible associations, not proof of causation in every case. Do not automatically change antihypertensive timing or order lifelong cessation of a systemic drug without coordinated review. No established treatment reliably restores lost vision; recurrence and fellow-eye counselling should reflect individual risk.